In particular, we provided evidence for the first time that HDACi ITF2357 is efficacious in a colon cancer model by upregulating lncH19 and is capable of overcoming 5-FU resistance in highly H19-expressing CRC cells. Here, H19 is linked to colonic neoplasm.